These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 7040746)

  • 1. Reduced antitumor and immune-adjuvant activities of the sub-cellular fractions from Group A Streptococcus.
    Ryoyama K; Natsuume-Sakai S; Hirota H; Koshimura S
    Jpn J Exp Med; 1981 Dec; 51(6):335-44. PubMed ID: 7040746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor activity of a Streptococcus pyogenes preparation (OK-432). I. Sequential effector mechanisms following a single OK-432 injection in F344 rats leading to the rejection of syngeneic MADB106 tumor cells.
    Fukui H; Reynolds CW
    J Natl Cancer Inst; 1987 Nov; 79(5):1011-7. PubMed ID: 3479632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation.
    Okamoto M; Furuichi S; Nishioka Y; Oshikawa T; Tano T; Ahmed SU; Takeda K; Akira S; Ryoma Y; Moriya Y; Saito M; Sone S; Sato M
    Cancer Res; 2004 Aug; 64(15):5461-70. PubMed ID: 15289356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative experiments with hemolytic streptococcus and its anticancer preparations (OK-431 and OK-432) for their cytolytic activity.
    Higuchi Y; Kigoshi S; Shoin S
    Jpn J Exp Med; 1980 Feb; 50(1):7-12. PubMed ID: 7382135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the properties of a streptococcal preparation OK-432 (NSC-B116209) as an immunopotentiator. I. Activation of serum complement components and peritoneal exudate cells by group A streptococcus.
    Sakai S; Ryoyama K; Koshimura S; Migita S
    Jpn J Exp Med; 1976 Apr; 46(2):123-33. PubMed ID: 778447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effect of OK-432-derived DNA: one of the active constituents of OK-432, a streptococcal immunotherapeutic agent.
    Oshikawa T; Okamoto M; Tano T; Sasai A; Kan S; Moriya Y; Ryoma Y; Saito M; Akira S; Sato M
    J Immunother; 2006; 29(2):143-50. PubMed ID: 16531815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of streptococcal acid glycoprotein produced by Streptococcus pyogenes Su.
    Kanaoka M; Fukita Y; Taya K; Kawanaka C; Negoro T; Agui H
    Jpn J Cancer Res; 1987 Dec; 78(12):1409-14. PubMed ID: 3123442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of protoplast membrane from group A streptococcus.
    Koshimura S; Ryoyama K; Ogawa H; Yamamoto A; Usami H; Mitsui H; Takagaki Y
    Jpn J Exp Med; 1977 Oct; 47(5):341-9. PubMed ID: 340733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Production of L-forms of Streptococcus pyogenes and their antitumor effects.
    Yamamoto A; Homma JY; Usami H; Sugawara Y
    Jpn J Exp Med; 1980 Oct; 50(5):383-8. PubMed ID: 7009927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Production of a cytotoxic factor in mouse peritoneal fluid by OK-432, a streptococcal preparation].
    Yamamoto A; Nagamuta M; Usami H; Sugawara Y; Watanabe N; Niitsu Y; Urushizaki I
    Gan To Kagaku Ryoho; 1986 May; 13(5):1905-10. PubMed ID: 3707150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-1 inducing activity of a streptococcal preparation OK-432 and its fractions by human monocytes.
    Katsuta S; Kaneko Y; Tsutsui K; Tamaki S; Ibata H; Chen DR; Suzuki S; Natsuume-Sakai S; Yamamoto A
    J Clin Lab Immunol; 1989 Mar; 28(3):129-36. PubMed ID: 2661826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumor immune response induced by the fractions derived from OK-432, a streptococcal preparation, by using a monoclonal antibody TS-2 that neutralizes the interferon-gamma-inducing activity of OK-432: comparison between the TS-2-binding and TS-2-unbinding fraction.
    Oshikawa T; Okamoto M; Ohe G; Furuichi S; Nishikawa H; Uddin Ahmed S; Yoshida H; Moriya Y; Matsubara S; Ryoma Y; Saito M; Sato M
    Int Immunopharmacol; 2003 May; 3(5):643-55. PubMed ID: 12757734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of antitumor activity of OK-432 (picibanil) by Triton X-114 phase partitioning.
    Hashimoto M; Takashige K; Furuyashiki M; Yoshidome K; Sano R; Kawamura Y; Ijichi S; Morioka H; Koide H; Oku N; Moriya Y; Kusumoto S; Suda Y
    Int Immunopharmacol; 2008 Jan; 8(1):12-9. PubMed ID: 18068095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blastogenic responses of human lymphocytes to a streptococcal preparation OK-432 and its fractions.
    Tanaka T; Kaneko Y; Haba F; Katsuta S; Tsutsui K; Tamaki S; Chen DR; Suzuki S; Ueda R; Yamamoto A
    J Clin Lab Immunol; 1989 Feb; 28(2):91-6. PubMed ID: 2787407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxic and antitumor effect of a fraction from cell-free extract of group A Streptococcus on transplantable tumor cells.
    Higuchi Y; Shoin S
    Anticancer Res; 1987; 7(6):1251-6. PubMed ID: 3327452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effect of Streptococcus pyogenes by inducing hydrogen peroxide production.
    Higuchi Y
    Jpn J Cancer Res; 1996 Dec; 87(12):1271-9. PubMed ID: 9045963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Experimental studies on specific active immunotherapy using immune response of irradiated tumor tissues. 5. A combined effect of the immune response of cryopreserved tissue and OK-432].
    Ogawa Y; Imanaka K; Gose K; Imajo Y; Kimura S
    Nihon Gan Chiryo Gakkai Shi; 1982 Aug; 17(5):1305-10. PubMed ID: 7153622
    [No Abstract]   [Full Text] [Related]  

  • 18. Antitumor activity of sediment fractions from Fusobacterium nucleatum culture supernatant.
    Tamai K; Watanabe K; Maeda T
    Jpn J Exp Med; 1984 Aug; 54(4):159-70. PubMed ID: 6513099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxic and cytostatic effects of the streptococcal preparation OK-432 and its subcellular fractions on human ovarian tumor cells.
    Nio Y; Zighelboim J; Berek J; Bonavida B
    Cancer; 1989 Jul; 64(2):434-41. PubMed ID: 2736490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Experimental studies on specific active immunotherapy using immune responses of irradiated tumor tissue. 4. Effects of a combined use of a non-specific immunopotentiator, OK-432].
    Imanaka K; Ogawa Y; Gose K; Imajo Y; Kimura S
    Nihon Gan Chiryo Gakkai Shi; 1982 Aug; 17(5):1299-304. PubMed ID: 7153621
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.